Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00365768 · ADVERSE EVENTS

Adverse events

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors · Source last updated 2016-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Not reported
Other-event reporting threshold
0%
Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Arm I: Glutamine

Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21. Glutamine: Administered orally twice daily for 21 days

0 / 240 / 24Not reported / Not reported
Arm II

Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21. Placebo: Administered orally twice daily for 21 days

0 / 250 / 25Not reported / Not reported

Group identifiers: EG000: Arm I: Glutamine · EG001: Arm II

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      event Groups
      1. description
        Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21. Glutamine: Administered orally twice daily for 21 days
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        24
        serious Num Affected
        0
        serious Num At Risk
        24
        title
        Arm I: Glutamine
      2. description
        Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21. Placebo: Administered orally twice daily for 21 days
        id
        EG001
        other Num Affected
        0
        other Num At Risk
        25
        serious Num Affected
        0
        serious Num At Risk
        25
        title
        Arm II
      frequency Threshold
      0

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice